Effect of rifampicin pre- and post-treatment on rotenone-induced dopaminergic neuronal apoptosis and alpha-synuclein expression

Neural Regeneration Research

Volumn 5, Issue 2, 2010, Pages 85-91

  Sun, Yuanlin ^a   Zhang, Guohua ^a   Xu, Jie ^a   Chen, Shiwen ^a   Tao, Enxiang ^a   Xu, Changqing ^b   Bennett, M Catherine ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Blanchette Rockefeller Neurosciences Institute   (United States)

Author keywords

Dopaminergic neurons; Parkinson's disease; Rifampicin; Rotenone; synuclein

Indexed keywords

ALPHA SYNUCLEIN; RIFAMPICIN; ROTENONE; SUNFLOWER OIL; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR DISORDER; BRAIN TISSUE; CHINA; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL LESION; NERVE DEGENERATION; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; SUBSTANTIA NIGRA; TREATMENT DURATION; WESTERN BLOTTING;

EID: 77949421501     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2010.02.001     Document Type: Article

References (36)

1. Shults CW. Lewy bodies. Proc Natl Acad Sci U S A. 2006;103(6): 1661-1668.
2. Liu H, Wang XZ. Alpha-synuclein and Parkinson disease. Neural Regen Res. 2007;2(4):239-243.
3. Xu J, Kao SY, Lee FJ, et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med. 2002;8(6):600-606.
4. Ono K, Hirohata M, Yamada M. Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders. Curr Pharm Des. 2008;14(30):3247-3266.
5. Namba Y, Kawatsu K, Izumi S, et al. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet. 1992; 340(8825):978.
6. Tomiyama T, Asano S, Suwa Y, et al. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun. 1994;204(1):76-83.
7. Kim S, Seo JH, Suh YH. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease. Parkinsonism Relat Disord. 2004;10 Suppl 1:S9-13.
8. Bradbury J. New hope for mechanism-based treatment of Parkinson's disease. Drug Discov Today. 2005;10(2):80-81.
9. Li J, Zhu M, Rajamani S, et al. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol. 2004;11(11): 1513-1521.
10. Xu J, Wei C, Xu C, et al. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-synuclein multimer. Brain Res. 2007;1139:220-225.
11. Oida Y, Kitaichi K, Nakayama H, et al. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. Brain Res. 2006; 1082(1):196-204.
12. Ubhi K, Rockenstein E, Mante M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport. 2008;19(13):1271-1276.
13. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
14. Fleming SM, Zhu C, Fernagut PO, et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol. 2004;187(2):418-429.
15. Heffner TG, Hartman JA, Seiden LS. A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav. 1980;13(3):453-456.
16. Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res. 2005;134(1): 109-118.
17. Yoo YM, Lee U, Kim YJ. Apoptosis and nestin expression in the cortex and cultured astrocytes following 6-OHDA administration. Neurosci Lett. 2005;382(1-2):88-92.
18. Chen Y, Constantini S, Trembovler V, et al. An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. J Neurotrauma. 1996;13(10):557-568.
19. Jenco JM, Rawlingson A, Daniels B, et al. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry. 1998;37(14):4901-4909.
20. Perez RG, Waymire JC, Lin E, et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci. 2002;22(8): 3090-3099.
21. Quilty MC, King AE, Gai WP, et al. Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp Neurol. 2006;199(2): 249-256.
22. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem. 2007;103(1):17-37.
23. Chandra S, Gallardo G, Fernández-Chacón R, et al. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005;123(3):383-396.
24. Rochet JC, Outeiro TF, Conway KA, et al. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci. 2004;23(1-2):23-34.
25. Andringa G, Lam KY, Chegary M, et al. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J. 2004;18(7):932-934.
26. Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett. 2002;320(3):146-150.
27. Ahn M, Kim S, Kang M, et al. Chaperone-like activities of alpha-synuclein: alpha-synuclein assists enzyme activities of esterases. Biochem Biophys Res Commun. 2006;346(4): 1142-1149.
28. Citron BA, Suo Z, SantaCruz K, et al. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int. 2002;40(1):69-78.
29. Mindermann T, Landolt H, Zimmerli W, et al. Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J Antimicrob Chemother. 1993;31(5):731-737.
30. Yulug B, Kilic U, Kilic E, et al. Rifampicin attenuates brain damage in focal ischemia. Brain Res. 2004;996(1):76-80.
31. Tomiyama T, Kaneko H, Kataoka K, et al. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J. 1997; 322(Pt 3):859-865.
32. Zhu M, Rajamani S, Kaylor J, et al. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem. 2004;279(26):26846-26857.
33. Conway KA, Rochet JC, Bieganski RM, et al. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001;294(5545):1346-1349.
34. Calleja C, Pascussi JM, Mani JC, et al. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat Med. 1998;4(1):92-96.
35. Gollapudi S, Jaidka S, Gupta S. Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs. J Clin Immunol. 2003;23(1):11-22.
36. Herr AS, Wochnik GM, Rosenhagen MC, et al. Rifampicin is not an activator of glucocorticoid receptor. Mol Pharmacol. 2000;57(4): 732-737.